Unforeseen new drug target discovered for acute myeloid leukemia

(Wellcome Trust Sanger Institute) A study reported in Nature has found an unexpected new drug target for acute myeloid leukemia that could open new avenues to develop effective treatments against this potentially lethal disease. Researchers from the Wellcome Trust Sanger Institute, the Gurdon Institute and their collaborators show that inhibiting the METTL3 gene destroys AML cells without harming non-leukemic blood cells and reveals why METTL3 is required for AML cell survival.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news